|
Overall
| | | | | | | | | | |
|
Patient Number
|
527,045
|
579,017
|
624,540
|
689,423
|
736,743
|
784,132
|
843,334
|
903,947
|
969,161
|
1,025,646
|
|
Volume/patient (DDDs)c.
|
585.94
|
613.85
|
640.25
|
650.54
|
652.36
|
651.68
|
653.71
|
637.1
|
630.16
|
635.59
|
|
Expenditure/patient (US$)d.
|
162.80
|
199.99
|
219.48
|
241.64
|
233.55
|
232.84
|
216.31
|
207.33
|
205.63
|
195.34
|
|
Subgroups by class
| | | | | | | | | | |
|
Volume/patient (DDDs)
c.
| | | | | | | | | | |
|
Biguanides
|
125.11
|
127.77
|
129.51
|
133.68
|
137.99
|
141.71
|
144.18
|
144.81
|
143.07
|
138.19
|
|
Sulfonylureas
|
449.33
|
453.46
|
458.54
|
444.33
|
421.16
|
410.44
|
399.74
|
379.16
|
354.72
|
325.44
|
|
Alpha-glucosidase inhibitors
|
3.64
|
5.97
|
10.72
|
13.81
|
14.67
|
16.13
|
18.04
|
19.35
|
19.34
|
19.21
|
|
Thiazolidinediones
|
3.23
|
16.04
|
27.48
|
34.15
|
31.15
|
32.64
|
36.64
|
37.44
|
36.66
|
38.4
|
|
Dipeptidyl peptidase-4 inhibitors
|
N/A b.
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
10.17
|
27.40
|
|
Othersa.
|
4.63
|
10.61
|
14.00
|
24.56
|
47.38
|
51.12
|
55.12
|
56.35
|
66.21
|
85.93
|
|
Expenditure/patient (US$)
d.
| | | | | | | | | | |
|
Biguanides
|
51.20
|
51.67
|
46.46
|
46.73
|
46.99
|
44.42
|
34.65
|
32.88
|
32.47
|
28.97
|
|
Sulfonylureas
|
94.38
|
98.10
|
95.10
|
98.36
|
96.40
|
94.07
|
85.00
|
81.35
|
74.84
|
59.13
|
|
Alpha-glucosidase inhibitors
|
4.94
|
7.41
|
12.46
|
15.81
|
16.52
|
17.87
|
18.54
|
18.45
|
17.39
|
15.06
|
|
Thiazolidinediones
|
7.70
|
33.85
|
53.87
|
66.64
|
60.65
|
62.64
|
64.40
|
60.83
|
55.67
|
48.42
|
|
Dipeptidyl peptidase-4 inhibitors
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
N/A
|
11.68
|
31.13
|
|
Othersa.
|
4.59
|
8.97
|
11.59
|
14.10
|
12.99
|
13.84
|
13.72
|
13.80
|
13.58
|
12.63
|
